Wednesday, October 27, 2021

Dr. Lal PathLabs Q2 FY22 | Analysis & Outlook

  


Dr. Lal PathLabs records revenue of Rs498.4cr in Q2 FY22

Net margins at 19.06% was lower than 19.75% on a yoy basis and it was sharply lower than NPM of 21.63% in Jun-21 quarter.


Dr. Lal PathLabs, a leading diagnostic and related healthcare services provider announced its financial results for the quarter ended September 30, 2021.

The net profit of the company was up by 11.37% to Rs95cr in the quarter ended September 2021 as against Rs85.30cr during the previous quarter ended September 2020. Also, the yoy profit growth was subdued because the raw material costs spiked by 25% on a yoy basis putting pressure on profit growth. Net margins at 19.06% were lower than 19.75% on a yoy basis and it was sharply lower than NPM of 21.63% in the Jun-21 quarter.

The Sales rose 15.40% to Rs 498.40 crore in the quarter ended September 2021 as against Rs 431.90 crore during the previous quarter ended September 2020.


Stock Outlook

Long term intact. 3126- 3204 good support zone .  Accumulate near this zone . Till wait.


Disclaimer- The information on this blog are based on my personal opinion and experience, it should not be considered professional financial investment advice and in no way it should be considered as a tip. We does not take any compensation of any kind whatsoever from any reader, user and company that are mention on this website. We are not SEBI registered financial advisor or analyst.


No comments:

Post a Comment